When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy,
fixed doses were recommended by the manufacturer. Awareness of the potential for a more …

This review aims to provide an update of the literature on the pharmacology and toxicology
of mycophenolate in solid organ transplant recipients. Mycophenolate is now the …

The transplantation literature includes numerous papers that report associations between
polymorphisms in genes encoding metabolizing enzymes and drug transporters, and …

The clinical application of mycophenolate mofetil (MMF) has significantly widened beyond
the prophylaxis of acute and chronic rejections in solid organ transplantation. MMF has been …

In association with therapeutic drug monitoring of immunosuppressive drugs,
pharmacogenetics has rapidly emerged as an additional tool to refine dose selection or …

Background Mycophenolic acid (MPA) is among the most commonly prescribed medications
for immunosuppression following organ transplantation. Highly variable MPA exposure and …

Mycophenolic acid (MPA), the active drug moiety of mycophenolate, is a potent
immunosuppressant agent, which is increasingly being used in the treatment of patients with …

O‐glucuronidation is the major metabolic elimination pathway for canagliflozin. The
objective was to identify enzymes and tissues involved in the formation of 2 major …

Mycophenolic acid (MPA) is widely used in paediatric kidney transplant patients and
sometimes prescribed for additional indications. Population pharmacokinetic or …

Mycophenolate mofetil (MMF) is used to prevent acute rejection following solid organ
transplantation in transplant centers all over the world. Patients from different ethnic …